Baudax Bio Inc (NASDAQ:BXRX) shares are surging after the company announced the acquisition of TeraImmune, a privately held biotechnology company focused on discovering and developing novel Treg-based cell therapies for autoimmune diseases.
“This merger adds TeraImmune’s TI-168 asset to the Baudax portfolio—a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients…with an Investigational New Drug (IND) application already FDA-cleared,” said Baudax Bio CEO Gerri Henwood.
“We believe this combination can enable, with a modest initial budget, activating the Phase 1/2a Clinical Trial of TI-168 for Treatment of HA,” Henwood added.
The company also said it would continue to progress the development of the existing Neuromuscular Blockade (NMB) portfolio at a prudent pace.
Recently, Baudax Bio announced additional results from its Phase 2 trial of BX1000 for NMB in patients undergoing elective surgery.
Additional electromyography (EMG) analyses of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium.
Price Action: BXRX shares are up 117.1% at $1.13 on the last check Friday.
